about
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second StrokesAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeThe effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) studyBenefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular riskDirect angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activationCardiovascular disease risk factors: epidemiology and risk assessment.Direct stimulation of angiotensin II type 2 receptor enhances spatial memoryEffect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (APrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre raReduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Telmisartan to prevent recurrent stroke and cardiovascular events.Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.Surrogate markers for cardiovascular disease: structural markers.Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combAlbuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Prospects for the prevention of stroke.Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.Prevention of stroke in patients with hypertension.Non-peptide AT2-receptor agonists.Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.Racial differences in incident heart failure during antihypertensive therapy.Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs.Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.Cardiovascular events during differing hypertension therapies in patients with diabetes.Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe.Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy.Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
P50
Q24645205-91E06CFA-FA39-4032-ABC7-464A71EF99F1Q24646522-757502D3-9FF2-40E8-BBF7-733C5BE43FC2Q28190480-038AFD27-C62C-4C92-B018-645339ABAFE9Q28194073-E7CABA61-9F09-4808-AB53-BBA97C98E399Q28485173-B7C2D398-4C4D-4C0A-A957-7B2B82AE7ACBQ30384873-A9C6045F-E8BF-47BB-9A05-2C6C98972D8DQ30504733-07AA58C9-24FF-410D-991E-B32223C25606Q30821209-3077E0E1-CAF4-44E6-9795-5A17612246DAQ33989952-572BD3DA-69B5-433D-A7E6-FB364379BB7BQ34189543-C4461F5B-C242-4787-9294-26E96CC8C3D2Q34414092-9254E906-D1CA-4231-83C5-927D49268253Q34522261-CF6AFB5B-6E4A-4E5B-B76F-DAD145FFEA84Q34596294-94F021AD-292C-461B-BF7E-171E91899E3FQ34714408-0FACAEB4-4624-40B1-B293-91BD290E097CQ35822626-900AECB9-5C8C-4CD4-9025-64944D8676B4Q35885669-A421A797-CEE5-48D3-9D82-5ED626A3AD6DQ35918678-0701B74F-3597-4642-85CB-133C7FB1666EQ36242359-01AEDC51-942C-45ED-913F-52BF9DE2F959Q36302833-0BA15E89-06A3-4318-A153-64FB3507DE77Q36443386-4DD53914-6F6D-4E46-963F-A64DE2430FA3Q36457568-95670D56-C9B2-4990-A012-EC309B5DAE10Q36731496-A87642EA-FB61-4582-AFE3-C47C19C5CF16Q36897546-95EDEDC6-979E-49F7-A805-8075967A75BAQ37822064-185E5DDD-B81F-46FB-84D0-48E87E6704CFQ38397719-586C513D-A575-4F8B-9A25-097B5915579BQ38410156-9EDAB880-7E8E-41CD-9AFC-BC2DAD17144CQ38432376-07CB65D3-F62F-4CDD-8069-9D5E00C31282Q38456183-66832590-25DE-4A47-8953-AC4A70BA6B49Q38494893-F8FB9277-88B5-4065-B2A4-EB0105DF4877Q38703613-B524B445-9455-4153-9D67-EBC271BAE057Q39317074-23126AD5-FF74-4FC9-BCBB-EEE9B305F010Q39858492-57F5249B-901C-4941-9B30-359EEC39A166Q39900531-C08008EF-77A4-490A-9F16-C84DAB577259Q39915071-258411F4-D0FF-4FC4-944A-326B80C47406Q39922300-79A745C2-5E1D-46F9-82F2-35F220309F0BQ40220508-700117D8-2D8C-4B49-BCE9-50785204015CQ40260838-9DCEBC6C-7C70-4599-A6FA-4993ADDB255FQ40347311-61940235-B940-4CD1-A931-2AFF3DBEA3E8Q41291894-6AE5E251-E02F-47FD-887D-574C5671C20CQ42162914-C35BBA69-1791-429E-A70C-ACEBFCD32700
P50
name
Björn Dahlöf
@ast
Björn Dahlöf
@en
Björn Dahlöf
@fr
Björn Dahlöf
@nl
type
label
Björn Dahlöf
@ast
Björn Dahlöf
@en
Björn Dahlöf
@fr
Björn Dahlöf
@nl
prefLabel
Björn Dahlöf
@ast
Björn Dahlöf
@en
Björn Dahlöf
@fr
Björn Dahlöf
@nl